Overview

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, single-blind, placebo-controlled, ascending single oral dose study designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Sunovion